Abstracts tagged "outcome measures and rheumatoid arthritis (RA)"

Abstract Number: 391 • 2012 ACR/ARHP Annual Meeting
DAS28 Is Not a Sufficient Disease Activity Measure for Obese Rheumatoid Arthritis Patients – Don’t Leave the Feet Behind
Vikram Garg¹, Paul Maranian², Mihaela B. Taylor³, Harold E. Paulus⁴, David Elashoff⁵ and Veena K. Ranganath⁶, ¹Division of Rheumatology, UCLA David Geffen School of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ²Division of Rheumatology, UCLA Medical School, Los Angeles, CA, ³Rheumatology, University of California Los Angeles, Los Angeles, CA, ⁴Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Departments of Biostatistics and Medicine, University of California, Los Angeles, Los Angeles, CA, ⁶Medicine/Rheumatology, University of California, Los Angeles, Western Consortium of Practicing Rheumatologists, Los Angeles, CA
Background/Purpose: Current literature suggests that obesity impacts disease activity in rheumatoid arthritis (RA) and the incidence of obesity is on the rise. The objective of…
Abstract Number: 398 • 2012 ACR/ARHP Annual Meeting
Basal Metabolic Rate As an Indicator of Rheumatoid Arthritis Disease Activity and Predictor of Remission
Heather Jones¹, Annette Szumski² and Andrew S. Koenig³, ¹Pfizer Inc., Collegeville, PA, ²Specialty Care, Pfizer Inc., Collegeville, PA, ³Specialty Care Business Unit, Pfizer Inc., Collegeville, PA
Background/Purpose: The role of body mass index (BMI) in rheumatoid arthritis (RA) disease activity and response to treatment has been difficult to determine.1 As a…
Abstract Number: 2609 • 2012 ACR/ARHP Annual Meeting
Construct and Criterion Validity of Several Proposed DAS28 Based Rheumatoid Arthritis Flare Criteria: A Cohort Validation Study
Aatke van der Maas¹, Elisabeth Lie², Robin Christensen³, Ernest Choy⁴, Yaël A. de Man⁵, Piet L.C.M. van Riel⁶, Thasia G. Woodworth⁷ and Alfons A. den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Copenhagen, Denmark, ⁴Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁵Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁷Medicine, Division of Rheumatology, Visiting Clinical Researcher, Geffen School of Medicine, UCLA, Los Angeles, CA
Background/Purpose: To enable consistent assessment of impact of tapering, withdrawal and dose optimization strategies, there is an increasing need for validated measures of flare in…
Abstract Number: 2134 • 2012 ACR/ARHP Annual Meeting
The Changed Prognosis of Patients with Early Rheumatoid Arthritis
Karin Britsemmer¹ and Dirkjan van Schaardenburg², ¹Rheumatology, Jan van Breemen Research Institute / Reade, Amsterdam, Netherlands, ²Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
The Changed Prognosis of Patients with Early Rheumatoid Arthritis Background/Purpose: The treatment of rheumatoid arthritis (RA) has changed greatly during the past fifteen to twenty…
Abstract Number: 2103 • 2012 ACR/ARHP Annual Meeting
Reliability of DAS28 in Rheumatoid Arthritis When Based On Patient Self-Assessment of Tender and Swollen Joints
Ole Rintek Madsen and Cecilie Heegaard, Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup, Denmark
Background/Purpose: Clinical assessment of disease activity is a routine procedure when evaluating individual rheumatoid arthritis (RA) patients in daily practice. Swollen joint count (SJC) and…
Abstract Number: 2106 • 2012 ACR/ARHP Annual Meeting
Patient Characteristics Associated with Discrepancies in Evaluator-Reported and Patient-Reported Outcomes in U.S. Veterans with Rheumatoid Arthritis
Archana Jain¹, Rebecca Belsom¹, Jeffrey R. Curtis², Shuo Yang³, Ted R. Mikuls⁴, Lang Chen⁵ and Angelo L. Gaffo⁶, ¹Rheumatology, University of Alabama, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Validated tools that incorporate evaluator and patient reported outcomes (PROs) are used for guiding therapy in patients with rheumatoid arthritis (RA). PROs used in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].